Comparing robotic, video-assisted, and open lung surgery after chemo-immunotherapy for lung cancer
An International Multicenter Retrospective Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy
This study looks at how well robotic, video-assisted, and open lung surgeries work for people with lung cancer after they’ve had chemo-immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Scientific Institute San Raffaele Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 6 sites (Miami, Florida and 5 other locations) |
| Trial ID | NCT06626243 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes medical records from patients diagnosed with locally advanced and resectable non-small cell lung cancer (NSCLC) who underwent lung resection using robotic, video-assisted thoracoscopic surgery (VATS), or open surgery after receiving neoadjuvant chemo-immunotherapy. The study aims to evaluate the short-term outcomes and oncologic efficacy of these surgical approaches. By examining data from five international centers, it seeks to provide insights into the feasibility and effectiveness of these techniques in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with locally advanced and resectable NSCLC who have undergone neoadjuvant chemo-immunotherapy and subsequent lung resection.
Not a fit: Patients who are under 18 years old or those who have not received neoadjuvant chemo-immunotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify the most effective surgical approach for patients with NSCLC after chemo-immunotherapy, potentially improving patient outcomes.
How similar studies have performed: While there is limited research directly comparing these surgical approaches post-chemo-immunotherapy, similar studies have shown promising results in evaluating surgical techniques for lung cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of clinical or pathological stage IIB (T1-2, hilar N1, M0) and III (any T, N1-2, M0) NSCLC surgically treated with robotic, VATS and open approach with radical intent from 1st of January 2016 to 31st of March 2024 * Received neoadjuvant chemo-immunotherapy or immunotherapy alone * Age \>= 18 years old at the moment of surgery Exclusion Criteria: * Age \<18 years old at the moment of surgery
Where this trial is running
Miami, Florida and 5 other locations
- Baptist Health South Florida — Miami, Florida, United States (Recruiting)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
- West Virginia University — Morgantown, West Virginia, United States (Recruiting)
- Istituto Clinico Humanitas — Rozzano, Milan, Italy (Recruiting)
- Scientific Institute Ospedale San Raffaele — Milan, Italy (Recruiting)
- Regina Elena National Cancer Institute — Rome, Italy (Recruiting)
Study contacts
- Study coordinator: Pierluigi Novellis, Medical Doctor
- Email: novellis.pierluigi@hsr.it
- Phone: 0226437202
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.